Single-chain antibodies (scFv) have an enormous potential for clinical application. However, rapid blood clearance and difficulties in large-scale production of active scFvs have limited the practical use of these antibody fragments. Recently, an anti-vascular endothelial growth factor (VEGF) scFv (scFv V65) was selected in our laboratory from a human antibody phage-display library. This antibody was able to reduce tumor growth in mice by approximately 50%. Here, we employ a gene therapy strategy for sustained in vivo expression of scFv V65 and its derivatives. scFv fusion proteins containing parts of the constant IgG1 region were generated (minibody and scFv V65-Fc) to increase the serum half-life of the scFv V65. Systemic administration of recombinant adenovirus encoding scFv V65 resulted in substantial tumor inhibition. This effect could be improved by multiple virus injections. We found that the efficacy of different scFv V65 formats was dependent on the mode of administration: whereas scFv V65-Fc was the most efficient when expressed locally, scFv V65 was superior when delivered systemically. Our results show that therapeutic levels of scFv V65 can be obtained by systemic injection of recombinant adenoviruses. Therefore, therapeutic gene delivery of scFv is a feasible strategy that overcomes several limitations of conventional antibody therapy.
Introduction
It is well established that angiogenesis, the sprouting of new capillaries from pre-existing blood vessels, is required for tumor growth and progression. 1 Therefore, blocking the process of tumor neoangiogenesis is a promising strategy to arrest tumor growth.
Extensive data have implicated vascular endothelial growth factor (VEGF) as a critical mediator of physiologic and tumor blood vessel formation. 2, 3 In contrast to other angiogenic growth factors, VEGF acts almost exclusively on endothelial cells, where its high-affinity tyrosine kinase receptors, KDR/Flk-1 and Flt-1, reside. 4, 5 Consequently, these molecules attract particular attention as targets for antiangiogenic therapy. VEGF is a multifunctional protein and not all of its functions can be substituted by other angiogenic factors. Indeed, multiple strategies on VEGF inactivation have been shown to be successful in reduction or even inhibition of tumor growth. 6 Monoclonal antibodies (mAbs) are attractive therapeutic agents due to their high specificity toward defined antigens. However, because of traditional obstacles in antibody therapy (immunogenicity of rodent-derived antibodies in humans, difficulties of producing antibodies in sufficient quantity and quality for commercial application), much attention has lately been paid to methodologies that enable the production of fully human antibodies in large scale. First, antibody phage technology has allowed the production of fully human antibodies from large antibody repertoires. 7 Second, in vivo production of antibodies following systemic administration of recombinant adenovirus avoids heterologous glycosylation patterns (eg rodent glycosylation on human antibodies produced in murine myeloma cells). Third, novel antibody formats have been developed (such as the single-chain Fv (scFv)), 8 which allow binding specificities to be encoded by a single polypeptide gene. In addition, scFv antibody fragments are much smaller in size than full immunoglobulins and are therefore more likely to penetrate into the tumor mass. 9 Our research interests are focused on the potential of genetically engineered antibodies for an antiangiogenic therapy. Recently, an anti-VEGF single-chain antibody (scFv V65) was selected in our laboratory from a human antibody phage-display library. This antibody was efficient in a chick CAM assay and was able to reduce the growth of subcutaneous tumors in nude mice by approximately 50%. 10 The delivery of antiangiogenic inhibitors using a gene therapeutic approach appears increasingly attractive. This strategy allows the synthesis of proteins of interest directly in the host and by this means overcomes the difficulties in large-scale production of active recombinant proteins. 11, 12 In the current paper, we explore the potential of viral gene therapy for sustained in vivo expression of the anti-VEGF scFv V65. We showed that even a single systemic administration of recombinant adenovirus encoding scFv V65 resulted in substantial tumor growth inhibition. This effect could be improved by multiple injections of recombinant adenovirus.
Since most scFvs have a short half-life in the blood, we aimed at increasing the serum circulation time of the scFv V65 by expressing it in two additional formats: as a minibody consisting of the scFv fused to the hinge and CH3 domain of human IgG1; and as an scFv-Fc fusion protein where scFv V65 was fused to the Fc portion of human IgG1. Constant regions of the IgG are routinely used in antibody engineering to obtain antibodies with properties similar to those of conventional antibodies (eg longer circulating half-lives, ability to dimerize, etc). 13, 14 However, these antibodies still consist of a single polypeptide chain and, unlike mAbs, are well suited for a gene therapy approach. Surprisingly, the efficacy of different scFv formats was found to be dependent on the mode of administration. While the scFv V65-Fc fusion protein had the strongest inhibitory effect when expressed locally, the scFv V65 was superior when the adenoviral vector was delivered systemically.
This work shows that a single injection of a recombinant adenovirus has a similar therapeutic effect as the frequent injections of high amounts of purified protein. Thus, the systemic delivery of a neutralizing anti-VEGF antibody fragment in a gene therapy setting can be considered as a valid alternative to therapeutic protocols based on the injection of purified antibody preparations, with potential advantages offered by the tissue penetration of the small scFv derivatives, their manufacture and the syngeneic glycosylation patterns, resulting from the in vivo antibody production that makes these antibodies potentially less immunogenic and better tolerated.
Results

Construction and characterization of adenoviruses encoding scFv V65 and its derivatives in vitro
In a previous report, we have described a single-chain antibody against VEGF which caused substantial tumor growth retardation if injected daily into tumor bearing animals. The aim of the current investigation was to (i) test whether the laborious preparation of sufficient amounts of purified protein could be circumvented by the use of the gene therapy strategy and (ii) evaluate whether the modifications of the scFv V65 aiming at prolonged serum half-lives lead to a stronger therapeutic effect of these antibody formats. Two forms of fusion proteins were generated. They contained either the hinge plus CH3 domain or the whole Fc region of an IgG.
To generate recombinant adenoviruses harboring these constructs as well as unmodified scFv V65, the DNA sequences encoding scFv, minibody and scFv-Fc were introduced into the pAdlox shuttle vector (Figure  1a , b; for details of the construction see Materials and methods). Recombinant adenoviruses, encoding each of these gene products were generated by Cre-lox-mediated recombination after CaPO 4 -mediated cotransfection of the different shuttle plasmids and the donor virus C5 DNA into CRE8 cells as described. 15 The resultant recombinant adenoviruses were plaque-purified, amplified in HER-911 cells and purified by two rounds of CsCl gradient centrifugation. The titers of recombinant adenoviruses as estimated by standard plaque assays were in the range of 1-3 Â 10 10 PFU/ml. To verify that the recombinant adenoviruses directed the expression of the desired proteins, Cos-7 cells were infected at an MOI 20, culture medium was collected 2 days later and analyzed for the presence of the anti-VEGF antibodies. The level of adenovirus-mediated expression of scFvs was sufficiently high to allow for the visualization on stained SDS/polyacrylamide gels ( Figure 2a ). Western blot analysis of cell culture medium under reducing conditions (Figure 2b ) demonstrated that the migration pattern of the secreted proteins was consistent with the predicted molecular weights of 28, 42 and 52 kDa for scFv V65, minibody and scFv V65-Fc fusion protein, respectively. Immunological mapping of the secreted proteins confirmed that they contain the scFv V65 part (Figure 2b, lanes 1-3) and part of the constant IgG region (minibody and Fc fusion protein) (Figure 2b, lanes 4-6) . Under nonreducing conditions, the apparent molecular weights of the minibody and Fc fusion protein were approximately 84 and 104 kDa, indicating that these polypeptides were able to form dimers (Figure 2c) .
These experiments demonstrated that the recombinant adenoviruses direct the synthesis of the desired proteins and that dimer formation within the IgG constant domain occurred efficiently.
Quantification of the expression level of different adenoviral constructs revealed that 3 Â 10 6 adenovirusinfected Cos cells grown in flasks produced approximately 3-5 mg/ml of scFv V65, 2-4 mg/ml of minibody 
Expression of the recombinant adenoviruses encoding scFv V65 and its derivatives in vivo
To evaluate the adenovirus-directed in vivo expression of the antibodies, 8 Â 10 8 PFU of recombinant adenoviruses were injected i.v. via the tail vein into nude mice. Small amounts of blood were taken from the tail vein every second day and the sera were analyzed for the expression level of scFv V65 and minibody by Western blot analysis and of scFv V65-Fc by ELISA. Purified scFv V65 and scFv V65-Fc were used as standards.
The kinetics of expression appeared to be similar for all recombinant adenoviruses (Figure 3a , c, minibody not shown) with the highest level of expression at days 2-6 post injection and a gradual decline thereafter. A single injection of Ad scFv V65-Fc provided very high levels of protein expression at day 2 post injection (1.2-1.6 mg/ ml) compared with Ad minibody (30-50 mg/ml) and Ad scFv V65 (5-7 mg/ml) (Figure 3b, c) . At day 12 post injection, the levels of scFv-Fc were still very high (210-350 mg/ml), intermediate for minibody (3-7 mg/ml) and very low for scFv V65 (approx. 600-700 ng/ml).
To demonstrate that the high levels of scFv V65-Fc and minibody did not result from a higher gene expression level, we performed Northern blot analysis of the RNA isolated from the livers of infected mice using an scFvspecific probe (Figure 3d ). This analysis showed that despite the mouse-to-mouse variations, there was no such striking difference between the expression of different adenoviral constructs in vivo at the RNA level as it was observed at the protein level. These data strongly suggest that a high level of scFv-Fc and, to a less extent, of a minibody in the blood was the result of the accumulation of these proteins in the blood due to prolonged half-lives of these antibody formats.
Comparison of the antiangiogenic activity of scFv V65 and its derivatives As the preparation of scFv for therapeutical use is very laborious, the efficacy of systemic scFv delivery by gene transfer using a recombinant adenovirus was tested. The ability of adenovirus-driven scFv V65 production to exert tumor growth inhibition was tested in a rat fibrosarcoma FE-8 model that was previously used to evaluate the antitumor effect of recombinant scFv V65 protein. 10 As we were not sure whether therapeutic levels of the antibody could be achieved upon systemic administration of recombinant adenoviruses, the extent of tumor growth inhibition by various formats of scFv V65 was estimated first by local expression in the tumor.
For local expression, FE-8 tumor cells were infected with the recombinant adenoviruses in vitro at an MOI 10 for 5 h, the cells were collected without trypsinization, resuspended in DMEM without FCS and injected into the flanks of nude mice. Toxicity of adenoviral infection was estimated with the help of an MTT test (Figure 4a ). It was found that under the selected conditions, infection of FE-8 cells with different recombinant adenoviruses did not significantly affect tumor cell proliferation in vitro.
In Figure 4b the effect of recombinant adenovirus infection on tumor growth is shown. Preinfection of FE-8 tumor cells with all three recombinant adenoviruses caused strong inhibition of tumor growth ( Figure 4b , dark bars). In contrast, the irrelevant NL antibody had no inhibitory effect as compared with uninfected control. infects primarily the liver, resulting in the secretion of the antiangiogenic proteins from liver cells into the blood stream. The dose of adenoviruses with maximal therapeutic effect and without adenovirus-mediated toxicity was selected in a dose-response experiment. It was found that a high dose of all recombinant adenoviruses tested (8 Â 10 8 PFU) was required for tumor growth inhibition. Figure 4b (light bars) shows the effect of the various recombinant viruses on tumor growth 10 days after tumor cell injection. Systemic expression of scFv V65 and the minibody resulted in an approximately similar extent of tumor growth inhibition (47% of tumor growth reduction, P¼0.0026 and 44%, P¼0.005, respectively). However, the scFv-Fc fusion protein had a weaker inhibitory effect (30%, P¼0.049) despite the much higher level of the protein in the blood of infected mice. Mean serum scFv-Fc level was 1.5 mg/ml (range 1.1-1.7 mg/ ml) as measured at day 3 post injection versus 48 mg/ml (range 35-55 mg/ml) for minibody and 6.9 mg/ml for scFv V65 (range 5-9 mg/ml). 
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These experiments show that all three formats of anti-VEGF antibody were able to inhibit tumor growth in different experimental settings. However, the antitumor effect of the different scFv V65 formats depended on the mode of administration: whereas the scFv V65-Fc fusion protein was most efficient when expressed locally, scFv V65 and minibody were superior when delivered systemically.
Effect of multiple adenovirus injections on tumor growth
In an attempt to increase antibody titers, we injected mice once, twice or three times with the recombinant adenoviruses (see Materials and methods, Figure 5a ). All mice tolerated the treatment with Ad scFv V65 well. However, multiple injections of Ad scFv-Fc and, to a less extent, Ad minibody caused toxicity to the mice. In particular, we observed accelerated blood coagulation in mice injected with the Ad scFv V65-Fc. It is unlikely that the observed toxicity is associated entirely with the anti-VEGF specificity of the antibody as it was also observed with an adenovirus directing the synthesis of an irrelevant scFv-Fc protein. This effect, however, was never observed in control mice injected with no Ad or with adenoviruses encoding other antibody formats. Therefore, in further experiments aiming at determining the maximal potential of current anti-VEGF treatment in our model, we only used Ad scFv V65.
As shown in Figure 5b , a single injection of Ad scFv V65 performed 2 days before tumor cell transplantation resulted in significant (45%) inhibition of tumor growth as compared to the control group of mice injected with Ad scFv NL. This effect was more pronounced in the group of mice receiving two injections of Ad scFv V65, with the second injection being performed 1 week after the first injection when the tumor was already well established (55% of inhibition in comparison to mice injected twice with Ad scFv NL, Figure 5c ). To increase the titers of anti-VEGF antibody maximally, we performed three injections of scFv V65, with the first two injections made prior to tumor cell implantation. The strongest inhibitory effect (73%) was observed in this group of mice (Figure 5d ). To confirm that repeated injections of recombinant adenovirus resulted in increased circulating levels of antibody, we examined the blood levels of scFv V65 in this group of mice. As shown in Figure 5f , the difference in the expression level of scFv 1-3) or twice (lanes 4-6) with the recombinant adenovirus. The sera were taken at the day of tumor cell implantation. The Western blot was developed with an anti-scFv V65 serum. The different lanes represent different mice. -3) , the concentration of the antibody increased after the second injection (418 mg/ml, lanes 4-6). Significantly, one, two or three injections of Ad scFv NL encoding an antibody with irrelevant specificity did not affect tumor growth significantly as compared to PBS-treated animals ( Figure 5 ). The tumor weights after autopsy were lower in mice treated with Ad scFv V65 than in control mice, consistent with the estimated tumor volumes (Figure 5e ). The observed tumor growth inhibition was statistically significant in all groups of Ad scFv V65-treated animals as compared to the control animals treated with Ad scFv NL (Po 0.05).
These results show that a single injection of recombinant adenovirus resulted in a substantial reduction of tumor growth. This effect can be improved through multiple injections of the recombinant adenovirus. Therefore, a gene therapy approach for sustained scFv V65 expression appears to be an attractive strategy that could replace the experimental protocol involving multiple injections of purified scFv V65 protein needed to obtain a similar therapeutic effect.
BIAcore
We have previously shown that scFv V65 targets VEGF both in vitro and in vivo.
10 scFv V65 binds to a mouse VEGF 164 (produced in Escherichia coli) and to a dog VEGF 120 (produced in Pichia pastoris) in ELISA; importantly, it showed antiangiogenic properties in a chick CAM assay. To demonstrate more directly the antibody specificity toward VEGF, we performed surface plasmon resonance studies using BIAcore to detect the real-time interaction between scFv V65 and VEGF. We fixed VEGF on the chip by an ED-B -anti-ED-B scFv bridge (see Materials and methods; Figure 6 , left part) such that VEGF was immersed in the solution and was readily accessible for anti-VEGF antibody. We found that the scFv V65-His 6 , produced in E. coli and originally selected on bacterially produced VEGF, was able to recognize VEGF produced in mammalian cells ( Figure 6 , right part). To get an impression about the scFv V65 affinity, we measured the kinetic parameters of the scFv V65-VEGF interaction. The rate constants k on and k off were determined to be 0. 
Discussion
Tumor angiogenesis is a complex process involving the interplay of multiple signal transduction pathways. VEGF/VEGFR II signaling occurs early during tumor development and plays a critical role in initial vascular formation, representing the rate-limiting step in tumor angiogenesis. 16 However, VEGF seems to play a broader role in the pathogenesis of cancer, influencing a number of processes involved in tumor-host interaction. VEGF is not only important for tumor vascularization, but is also a key factor produced by solid tumors to inhibit recognition and destruction of tumor cells by the immune system. 17, 18 In addition, VEGF is implicated in the paraneoplastic syndrome, a condition associated with a higher morbidity and mortality than would be expected from the actual tumor burden. 19 Therefore, the inhibition of VEGF activity seems to be beneficial not only for tumor growth inhibition and metastasis prevention, but also might improve immunotherapy and the general condition of cancer patients.
The high specificity of monoclonal antibodies makes them particularly well suited for medical use. However, mouse mAbs have limited application in human clinical trials because of their immunogenicity. This has driven the development of alternative systems for the rapid production of highly specific human antibody fragments. Developed in recent years, phage-display technology has improved the ability to select for human-derived singlechain antibodies (scFv) that have desirable properties for immunotherapy. scFv's are the smallest antibody fragments retaining the ability to interact with a defined antigen. Because of their small size, scFv fragments can penetrate tumors much more easily than mAbs and they are less immunogenic. However, rapid blood clearance, which is common to such small molecules, with a halflife shorter than 30 min for the a phase of the blood clearance profile 9, 20 results in the necessity of frequent delivery of such antibody fragments.
A single-chain anti-VEGF antibody selected in our laboratory from a phage-display library was shown to partially inhibit the growth of subcutaneous tumors in nude mice. 10 Inhibition of tumor growth in our model required daily injections of high doses of the purified recombinant scFv to maintain the therapeutic effect. An attractive alternative way to obtain sustained therapeutic concentration of the antibody is a gene therapy approach. For this purpose, we chose to use recombinant adenoviruses because they provide high level of transgene expression. When administered intravenously, adenoviral infection occurs primarily in the liver resulting in the secretion of the desired proteins into the blood of infected animals; therefore, the effect of the expression product on tumor growth is mediated mainly by a systemic mechanism. Gene therapy of anti-VEGF scFv TA Afanasieva et al
To ensure a sufficiently high concentration of anti-VEGF antibody in the blood, we attempted to increase the half-life of the scFv by generating a minibody consisting of the anti-VEGF scFv linked to the hinge and CH3 domain of human IgG1 as well as an scFv-Fc fusion construct. The half-life of antibody is determined by its ability to bind to the neonatal Fc receptor (FcRn), 21 and human IgG1 retains its ability to interact with mouse FcRn. 22 In addition to a half-life improvement, these modifications aimed to increase the apparent affinity of the fusion proteins for VEGF through a higher valency. Within the constant part of the IgG, disulfide bridges are formed and both the Fc fusion protein and the minibody associate into dimers. The resulting bivalent fusion proteins closely resemble the structure of intact IgG. However, in contrast to mAbs, they consist of a single polypeptide chain that makes them suitable for gene therapy approaches.
We constructed a set of recombinant adenoviruses expressing different formats of anti-VEGF scFv (scFv V65, minibody and scFv-Fc fusion protein). All three formats of the scFv were produced in similar amounts in cultured cells. However, the blood level differed significantly, the Fc fusion protein and the minibody being approximately 50 and 3 times more abundant than the scFv V65. This argues in favor of prolonged serum half-life of the fusion derivatives, mainly of the scFv-Fc protein.
We investigated the effect of the different formats of anti-VEGF scFv on tumor growth in experiments with local and systemic antibody expression. Interestingly, the efficacy of different scFv V65 formats was dependent on the mode of application: whereas scFv and minibody were the most efficient if delivered systemically, the scFv-Fc molecule was superior when expressed locally by tumor cells. We assume that a prolonged half-life and, as a consequence, a greater availability within the tumor may account for the stronger inhibitory effect of local scFv-Fc expression. If anti-VEGF scFv is able to recognize the VEGF-Flk1 complex on endothelial cells, an additional Fc-mediated cytotoxic effect might contribute via the interaction with the complement components or natural killer cells. This can also explain a weaker inhibitory effect of local expression of minibody, which lacks the effector CH2 domain necessary for a complement activation.
The finding that systemic administration of scFv V65 adenovirus resulted in a greater antitumor response than scFv V65-Fc even though circulating levels of scFv V65 were 50-fold less than those of scFv V65-Fc was quite unexpected. The reason for this difference is unclear for us at the moment and additional pharmacokinetic studies could possibly help to explain this result. However, it is known that the whole antibodies penetrate solid tumors with a rather low efficiency that results from their large size and retention by Fc receptors found in most tissues. The same could hold true in our experiments and result in relatively late achievement of efficient scFv V65-Fc concentration within the tumor.
Our experiments suggested that, among the three antibody formats tested, scFv V65 was the one best suited for systemic application in a gene therapy setting. We found that a single injection of a recombinant adenovirus expressing the scFv V65 results in substantial tumor growth inhibition, which was comparable to the effect we found by injecting the purified protein daily in high amounts. This effect can even be improved by multiple injections of the recombinant adenovirus. To obtain the quantitative characteristics, we measured the interaction between mVEGF 164 and anti-VEGF scFv-His 6 in a BIAcore assay. With a K d of 7.2x Â 10 À7 M, approximately 20 mg/ml of scFv V65 is required to inactivate 50% of the VEGF. The working concentration of the antibody observed in our experiments is somewhat lower. On the one hand, it could be that the K d value in blood differs from the one measured in aqueous solution. Furthermore, we cannot exclude that the immunoreactivity of the E. coli-produced scFv used in affinity measurements is not complete, leading to the low apparent kinetic association constant k on measured. It is likely that in vivo-produced scFv fragments are well folded and immunoreactive. We have observed on several occasions that antibody fragments expressed in mammalian cells display better properties (eg solubility, stability) than the same antibody fragment expressed in E. coli.
It is reasonable to assume that the therapeutic effect of an anti-VEGF antibody fragment is mainly dictated by the relation between serum concentration and dissociation constant K d . We attempted to increase the affinity of V65 using an in vitro affinity maturation procedure, which features the randomization of residues in the CDR3 region of the variable light chain domain. 23, 24 Newly selected affinity matured scFvs showed enhanced binding to mVEGF in ELISA and improved antiangiogenic properties in a CAM assay (A vitaliti and R Klemenz, unpublished results). Whether these scFv variants will show improved performance in vivo (either in terms of increased antitumor potency or lower doses needed) remains to be seen.
The concentration of the antibody, which is determined mainly by the level of production, is another important parameter. Development of viral vectors allowing for a long-term expression 25, 26 combined with a targeted delivery and/or cell-specific expression of therapeutic proteins 27,28 will allow to increase the level of antibody production while reducing the vector and transgene-associated toxicity. In addition, the combination of antiangiogenic therapy using recombinant adenoviruses encoding scFv V65 and its derivatives and radio-or low-dose chemotherapy, which proved to be beneficial for other antiangiogenic drugs, [29] [30] [31] can be a useful strategy to improve the performance of the anti-VEGF scFv.
In summary, gene therapy delivery of scFv as a single neutralizing agent is a feasible strategy allowing achievement of therapeutic levels of scFv in the blood. Rapid clearance of scFvs, which is considered to be the major obstacle for an application of this antibody format, can be compensated by sustained in vivo production using the gene therapy approach as is shown here and recently by other groups. 32, 33 Therefore, the approach described here may be a powerful strategy for a rapid validation of therapeutic efficacy of various antibody fragments and potentially, with improved viral systems of delivery and selection of scFv with the enhanced affinity, may offer an alternative to a conventional antibody therapy. , Switzerland) , respectively, and were used for adenovirus preparation. Cos-7 cells were obtained from E Frö hli (Zurich University, Switzerland) and were used for expression analysis of recombinant adenoviruses. All cell lines were grown in DMEM containing 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine. All reagents were purchased from Gibco/BRL, Switzerland.
Anti-VEGF scFv V65 was selected in our laboratory from the Nissim antibody phage-display library. 10 The irrelevant scFv (scFv NL) with unknown specificity was a by-product of the scFv V65 selection and therefore shares a variable light chain domain but has a variable heavy chain domain different from that of the anti-VEGF scFv. scFv NL does not bind to VEGF and other antigens tested in the previous study in ELISA, does not have an antiangiogenic activity in a CAM assay and in an in vivo tumor model when used as a purified protein. 10 Inbred Balb/c athymic nu/nu mice (Charles-River, Sulzfeld, Germany), 6-8 weeks old, were used for animal experiments. All regulated procedures involving experimental animals were carried out under a project and personal license issued to RK by the Kantonales Veterinäramt des Kantons Zü rich (Bewilligung 118/ 2000).
Generation of the constructs encoding minibody and scFv V65-Fc fusion protein
Constructs encoding scFv V65, minibody and scFv-Fc were assembled in the plasmid pGEM-T (Invitrogene). First, the signal peptide sequence of the orphan T1 receptor was PCR amplified using the T1 cDNA plasmid pT1.11 35 as a template. The upper primer (5 0 -CGGAATTCCACCATGATTGACAGACAGAGAATG-3 0 ) introduced an Eco RI cloning site (italics) and a consensus Kozak sequence (underlined) for optimal protein translation initiation. The lower primer (5 0 -CGCAAGCTTACTGCCCTCCGTAACTGTC-3 0 ) introduced a Hind III cloning site (italics). The PCR product was cloned into the Eco RI/Hind III cloning sites of pGEM-T. The scFv V65 fragment was amplified using the plasmid pDN268 10 with the scFv V65-specific primers introducing a Hind III cloning sites at the 5 0 end and Xba I and Hind III sites at the 3 0 end. The PCR product was cut with Hind III and cloned into the Hind III site downstream of the T1 signal peptide sequence.
To create an scFv-minibody construct, a human IgG1 hinge-CH3 fragment was generated using a pT1IgG plasmid as a template (Figure 1a) . The hinge fragment was produced with the primers IgG-A (5 0 -GCGGCTCTA GAGAGCCCAAATCTTGTGACAAAACTCACACATGC CCACCG-3 0 , Xba I in italics) and IgG-B (5 0 -GTGGTTCTCGGGGCTGCCCTGGGCAACGTGGGCAT GTGTGAGTTTTG-3 0 , the sequence overlapping with the CH3 sequence is underlined). The CH3 fragment was PCR amplified with the primers IgG-C (5 0 -GCCCAGGG CAGCCCCGAGAACCAC-3', the sequence overlapping with the hinge sequence is underlined) and IgG-D2 (5 0 -GGCGCTCTAGAGCGGCCGCTCATTTACCCGGAG ACAGG GAGAG-3 0 ,the stop codon is in bold and the Not I and Xba I sites are in italics). The CH3 and hinge fragments were annealed and PCR was performed with the primers Ig-A and IgG-D2. A human IgG1 Fc fragment was PCR amplified with the primers IgG-A and IgG-D2. Xba I fragments of assembled minibody and Fc sequences were cloned into the Xba I site downstream of the scFv V65 sequence. The constructs encoding the derivatives of the irrelevant scFv (scFv NL) were constructed in the same way and the identity of all fragments was verified by sequencing.
Construction, generation and purification of recombinant adenoviruses encoding scFv V65 and its derivatives
To generate the recombinant adenoviruses, a system was used that allowed Cre-lox recombination between the pAdlox shuttle plasmid and the donor virus C5 DNA. 15 . To facilitate the cloning procedure, the polylinker of a shuttle plasmid pAdlox was replaced with the sequence containing an Eco RI, Xho I and Not I restriction site and multiple stop codons (pAdlox.mod). Eco RI/Not I fragments of assembled minibody and scFv-Fc sequences were cloned into the Eco RI/Not I sites of pAdlox.mod (Figure 1b) . To create the adenoviral plasmid containing only the scFv sequence, the pAdlox.mod-svFv-Fc plasmid was digested with Xba I and Not I to remove the IgG part, the overhangs were filled in with Klenow fragment and the plasmid was religated (Figure 1b) .
pAdlox.mod plasmids containing the sequences of scFv and its derivatives were digested with Sfi I and cotransfected with C5 donor viral DNA into CRE8 cells. Lysates of CRE8 cells were prepared by three cycles of freeze-thawing and were used to infect HER-911 cells. Viral plaques were isolated and viral DNA was extracted by a modified Hirt assay. Recombination was verified by restriction enzyme and protein analysis of infected cells. Recombinant adenoviruses were purified by two rounds of CsCl gradient centrifugation. The titers of purified adenoviruses were determined by a standard plaque assay on HER-911 cells and the viral stocks were stored at À701C until use.
Expression analysis of recombinant adenoviruses in vitro
Cos-7 cells were infected with the recombinant adenoviruses at an MOI 20. At 3 h after infection, the medium was changed to nutridoma medium (Boehringer Mannheim, Germany). After 2 days the culture medium was harvested, cellular debris were removed by centrifugation and the secreted proteins were analyzed by SDS/ PAGE and/or Western blot analysis. For the detection of scFv V65, an antiserum was raised in rabbits by immunization with recombinant scFv V65-His 6 produced in E. coli and purified on an Ni-agarose column. 10 Western blots were incubated with a 1:100 dilution of the anti-scFv V65 serum for 2 h and subsequently with either HRP-or AP-conjugated goat anti-rabbit IgG at 1:7000 for 1 h (Jackson ImmunoResearch). For the detection of the Fc part, an HRP-conjugated anti-human IgG (Fc specific) antibody was used (1:8000; Southern Biotechnology, Birmingham, AL, USA).
Expression analysis of recombinant adenoviruses in vivo
Small amounts of blood were collected from the mouse tail veins after i.v. adenovirus injection and the sera were used for analysis. Quantification of the expression level of scFv V65 and the minibody was carried out by Western blot analysis as described above using purified scFv V65-His 6 as a reference. The level of expression of the scFv V65-Fc fusion protein was quantified by ELISA. Purified scFv V65-Fc fusion protein was used as the reference. Immunoplates (Xenobindt, Nunc, Live Technology) were coated overnight with 10 mg/ml mVEGF 164 -His 6 .
10 Nonspecific binding was blocked with 2% milk powder in PBS for 2 h. After 1 h incubation of 0.1 ml of sera in 100 ml of 2% milk/PBS, the wells were extensively washed and incubated with an HRP-conjugated anti-human IgG (Fc specific) antibody (1:8000, 1 h; Southern Biotechnology, Birmingham, AL, USA) for an additional hour. The ELISA was developed using BM blue POD substrate (Roche, Switzerland) and the A 450 nm was measured.
RNA preparation and Northern blot analysis
Frozen. livers of adenovirus-infected mice were smashed on dry ice and total RNA was isolated. Isolation of the RNA and Northern blot analysis were essentially performed as described. 10 For hybridization, an scFv V65 DNA probe generated by PCR and labeled by random oligomeric primer extension (Random Primed DNA labeling kit, Boehringer, Mannheim, Germany) was used. After development, the blot was stripped and rehybridized with an internal control probe (b-actin).
Animal experiments
To evaluate the antiangiogenic effect of the antibodies, recombinant adenoviruses were either applied systemically or used to infect the tumor cells before they were injected into mice. To that end, FE-8 cells were infected in vitro with the recombinant adenoviruses at an MOI 10 during 5 h and injected into the flanks of nude mice. To evaluate the toxicity of adenoviral infection on these cells, an MTT test was performed according to the protocol of the manufacturer (Promega, Wallisellen, Switzerland).
To estimate the effect of systemic expression of various adenoviruses, 8 Â 10 8 PFU of recombinant adenoviruses were injected i.v. via the tail vein in a final volume of 100 ml. Virus dilution in PBS was performed immediately before injections. The controls were also carried out with PBS alone at 100 ml per mouse. FE-8 tumor cells (1 Â 10 6 per site) were implanted into both flanks of nude mice 2 days later. For an adenovirus multiple injections study, one, two or three Ad scFv V65 injections were performed as shown in Figure 5a (days À7, À2 and 5 relative to the day of tumor cell implantation). FE-8 tumors were allowed to grow for 10 days when control tumors reached a volume of approximately 1 cm 3 . The size of the tumors was measured with a calliper and the tumor volume was calculated using the formula: tumor volume¼1/2 (width) 2 Â length. At the end of the experiment, the animals were killed, and the tumors removed and weighted. The final results were calculated as means þ s.e. for each group of animals. P-values were determined by using a two-tailed t-test assuming unequal variances (Microsoft EXCEL). The difference was considered to be statistically significant when Po 0.05.
BIAcore
The binding properties of scFv V65 to a mouse VEGF 164 was investigated by real-time interaction analysis with surface plasmon resonance detection, using a BIAcore 300 instrument (Biacore, Freiburg, Germany), according to established protocols. 23, 36 Biotinylated ED-B domain of fibronectin was applied to a streptavidin-coated microsensor chip followed by an anti-ED-B scFv L19-VEGF 164 fusion protein injection. 37 Binding studies were performed using 7 mM purified scFv V65-His 6 solution in PBS (50 mM phosphate buffer (pH 7.2)-100 mM NaCl), with a 5 ml/min flow. The sensorgrams were evaluated using the BIA Evaluation 3.0 program, and the rate constants k on and k off and the dissociation constant (K d ) were determined.
